Compare Organon Pharma Indonesia Tbk. (SCPI) vs Mizuho Leasing Indonesia Tbk. (VRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon Pharma Indonesia Tbk. vs Mizuho Leasing Indonesia Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Mizuho Leasing Indonesia Tbk. trades at Rp91 (market cap 534.61B, 3.04M 24h volume). The key difference: Mizuho Leasing Indonesia Tbk. is far larger — about 5.1× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | VRNA | |
|---|---|---|
Market Cap | 104.4B | 534.61B |
Volume | — | 3.04M |
Lot | — | 30.36K |
Turnover | — | 276.96M |
Average Price | — | 91.21 |
Value | — | 276.96M |
Indicative Equilibrium Price | — | 91 |
Indicative Equilibrium Volume | — | 8.99K |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →About Mizuho Leasing Indonesia Tbk.
PT Verena Oto Finance (the Company) was established under its original name of PT Maxima Perdana Finance base on notarial deed No.43 of Mrs Sri Nanning, S.H, dated on Jul 21, 1993. The Companys articles of association has been amended several times, most recently by notarial deed No. 32 of Fathiah Helmi, S.H., dated Mar 26, 2007, concerning among others, the change in the Companys name, increase authorized, change in par value, and increase paid-up capital.
Read more on VRNA →
